Skip to main content

Psoriatic arthritis

Which patients with psoriasis are at risk to develop PsA?

The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum.



Many patients do have psoriasis before onset of symptoms. This question can either be explored retrospectively using existing data or

Read Article

EULAR 2021 – Day 4 Report

Jun 17, 2021

It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.

Read Article
Ten Things to Tell Patients About Diet and Rheumatic Disease: Dr. Eric Dein ( @ejdein1 ) https://t.co/q2Mc1gLZig https://t.co/iV5JO8m5Sv
Dr. John Cush @RheumNow( View Tweet )
Jun 16, 2021
Psoriatic arthritis (PsA) is a chronic condition with manifold clinical presentations. Health issues may be far beyond the classical associated conditions like uveitis, enthesitis etc. https://t.co/zHfeaiiG93

Dr. John Cush @RheumNow( View Tweet )

Jun 16, 2021

Artificial intelligence brings clarity to early bony changes in inflammatory arthritis

Jun 16, 2021

Subtle early bony changes in inflammatory arthritis can be hard even for experienced rheumatologists to interpret, even though they have traditionally been considered to become disease-defining as they progress. As computational techniques have become more sophisticated and more accessible,

Read Article

Psoriatic arthritis mortality & morbidities

Psoriatic arthritis (PsA) is a chronic condition with manifold clinical presentations. Health issues may be far beyond the classical associated conditions like uveitis, enthesitis etc. The current study of Tillett et al (OP0231) assessed comorbidities and patient characteristics comparing

Read Article
Popular article alert! New GRAPPA 2021 PsO and PsA Treatment Recommendations Dr. Rachel Tate ( @uptoTate ) shares insights from abstract #OP0229 at #EULAR2021. https://t.co/AnHQGA8aKs https://t.co/9Acnzofiu4
Dr. John Cush @RheumNow( View Tweet )
Jun 14, 2021
How do we personalize psoriatic arthritis treatment? Dr. Robert Chao ( @doctorRBC ) discusses presentation 6937 from #EULAR2021. https://t.co/1d9IsSqr0n https://t.co/ZbHwdWimgL
Dr. John Cush @RheumNow( View Tweet )
Jun 12, 2021

RheumNow Podcast - Best of EULAR 2021

Jun 11, 2021

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article

Q-DAPSA for Measuring Disease Activity in PsA

Jun 10, 2021

Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain comprehensive and validated.

Read Article
Video: Treatment Options for PsA Patients: Dr. Paul Studenic Dr. Paul Studenic reviews highlights from three PsA abstracts - abstract op0227, abstract op0229, and abstract op0233 - presented at the virtual #EULAR2021 meeting. https://t.co/QlquUQFQOJ https://t.co/p5wBTboIpE
Dr. John Cush @RheumNow( View Tweet )
Jun 09, 2021
Psoriatic arthritis mortality & morbidities by Dr. Paul Studenic #EULAR2021 PsA is a chronic condition with manifold clinical presentations. Health issues may be far beyond the classical associated conditions like uveitis, enthesitis etc. https://t.co/zHfeaiiG93 https://t.co/AoHenH6YkK
Dr. John Cush @RheumNow( View Tweet )
Jun 09, 2021
Video: The PsA SpA Paradox of Choice Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting. https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2021
New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptotate) The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. Read more... https://t.co/AnHQGA8aKs https://t.co/4c18j4h54T
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2021
Video: Personalization of PsA Treatment: Dr. Robert Chao ( @doctorRBC) Dr. Robert Chao reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented #EULAR2021. https://t.co/LeocvUyZ7N https://t.co/g6ApPL0Pui
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2021
#EULAR2021 - Day 3 Report https://t.co/X7zxsKW8eL https://t.co/OKu5Mgodlo
Dr. John Cush @RheumNow( View Tweet )
Jun 08, 2021

EULAR 2021 - Day 3 Report

Jun 07, 2021

Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.

Read Article

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

Read Article

How do we personalize psoriatic arthritis treatment?

Jun 07, 2021

It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it?



Oral presentation (6937) discussed that issue and addressed our need for a more personalized approach to the treatment of PsA. 

Read Article

Israel provides COVID vaccine answers for rheumatic disease patients

Jun 07, 2021

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a broad scale, has

Read Article
@IainBMcInnes1 @NEJM @JWatch @NEJMres360 #rheumatology #rheumtwitter #MedTwitter #VisualAbstract #WorldASDay #spondyloarthritis #psoriasis #psoriaticarhtritis #MedEd #dermatology #JAKi #EBM https://t.co/dGRi83Wt9x https://t.co/22WacHQZpT
EnvisionRheumat @ERheumat( View Tweet )
Jun 06, 2021
➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Jun 06, 2021
⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX) -Tx . (TP)1: SEC 75/100 mg till wk 12 -TP2: cont SEC or switch to PBO till wk 104 ⭐️SEC efficacious on JIA ACR30/70 ⭐️74% w/ resolution of enthes ⭐️Median T2flare in PBO in TP2 = 453d LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Jun 06, 2021
No clear winner here. The majority would use #IL23 inhibitors as either 2nd or 3rd line bDMARDs and for #psoriaticarthritis with severe #psoriasis. Thank you for participating in the polls #EULAR2021 @RheumNow https://t.co/b8wzaRVTqw

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

Jun 06, 2021
6. Rheum disease activity was stable with COVID vaccination. (RA, PsA, axSpA, SLE - total n = 597) 7/ LB0003 #EULAR2021 @RheumNow https://t.co/xxkrunjPa0
David Liew @drdavidliew( View Tweet )
Jun 06, 2021
×